This site uses cookies to store information on your computer. Some are essential to make our site work; others help us improve the user experience. By using the site, you consent to the placement of these cookies. You may at any time change the settings regarding cookies. Read our privacy statement to learn more.
Medtronic offers a comprehensive portfolio of solutions designed to help improve care of chronic GI diseases and cancers. Our technologies can assist with patient management through early detection and treatment.([FOOTNOTE=Lacy BE, et al. Clinical utility of the wireless pH capsule. J Clin Gastroenterol. 2011;45:429-35.],[ANCHOR=],[LINK=]),([FOOTNOTE=Sweis R, Fox M, Anggiansah A, Wong T. Prolonged, wireless pH studies have a high diagnostic yield in patients with reflux symptoms and negative 24hr catheter-based pH studies. Neurogastro Motil. 2011;23(5):419-26.],[ANCHOR=],[LINK=]),([FOOTNOTE=Richter JE, Pandolfino JE, Vela MF, Kahrilas PJ, Lacy BE, Ganz R, et al. Utilization of wireless pH monitoring technologies: a summary of the proceedings from the esophageal diagnostic working group. Dis Esophagus. 2013;26(8):755-65.],[ANCHOR=],[LINK=]),([FOOTNOTE=Vela MF. Diagnostic work-up of GERD. Gastrointest Clin N Am. 2014;24(4):655-66.],[ANCHOR=],[LINK=]),([FOOTNOTE=Karamanolis G, Kotsalidis G, Triantafyllou K, Polymeros D, Gaglia A, Fessatou S, et al. Yield of combined impedance–pH monitoring for refractory reflux symptoms in clinical practice. J Neurogastroenterol Motil. 2011;17(2):158-63.],[ANCHOR=],[LINK=]),([FOOTNOTE=Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398-402.],[ANCHOR=],[LINK=]),([FOOTNOTE=Kawamura O, Hosaka H, Shimoyama Y, Kawada A, Kuribayashi S, Kusano M, et al. Evaluation of proton pump inhibitor-resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impendence and pH monitoring. Digestion. 2015;91:19-25.],[ANCHOR=],[LINK=]),([FOOTNOTE=Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 2013;108(8):1238-49.],[ANCHOR=],[LINK=]),([FOOTNOTE= Bansal A, Kahrilas PJ. Has high-resolution manometry changed the approach to esophageal motility disorders? Curr Opin Gastroenterol. 2010;26:344-51.],[ANCHOR=],[LINK=]),([FOOTNOTE=Lee YY, Erdogan A, Rao SSC. High resolution and high definition anorectal manometry and pressure topography diagnostic advance or a new kid on the block. Curr Gastroenterol Rep. 2013;15:360.],[ANCHOR=],[LINK=]),([FOOTNOTE=Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Eng J Med. 2009 May;360(22):2277-88.],[ANCHOR=],[LINK=]),([FOOTNOTE=Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1-10.],[ANCHOR=],[LINK=]),([FOOTNOTE=Dionisio PM, Gurudu SR, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2010;105(6):1240-8.],[ANCHOR=],[LINK=]),([FOOTNOTE=Eliakim R, Yassin K, Niv Y, Metzger Y, Lachter J, Gal E, et al. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonscopy. Endoscopy. 2009;41:1026-31.],[ANCHOR=],[LINK=]),([FOOTNOTE=Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett’s esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2009 Jun;104(6):1533-9.],[ANCHOR=],[LINK=]),([FOOTNOTE=Sarosiek I, Selover KH, Katz LA, Semler JR, Wilding GE, Lackner JM, et al. The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. Aliment Pharmacol Ther. 2010 Jan 15;31(2):313-22.],[ANCHOR=],[LINK=]),([FOOTNOTE=Wani S, Muthusamy VR, Komanduri S. EUS-guided tissue acquisition: an evidence-based approach (with videos). Gastrointest Endosc. 2014;80(6):939-59.],[ANCHOR=],[LINK=]),([FOOTNOTE=Spada C, Hassan C, Munoz-Navas M, Neuhaus H, Deviere J, Fockens P, et al. Second-generation colon capsule endoscopy compared with colonscopy. Gastrointest Endosc. 2011 Sep;74(3):581-9.],[ANCHOR=],[LINK=])
The PillCam™ capsule endoscopy platform provides clear images([FOOTNOTE=User Manual (DOC-2044-02 March 2013), page 8.],[ANCHOR=],[LINK=]) and allows for the visualization of the esophagus, stomach, duodenum, small bowel, and colonic mucosa.([FOOTNOTE=User Manual (DOC-2044-02 March 2013), page 103],[ANCHOR=],[LINK=]) This platform enables physicians to detect chronic diseases, visualize disease activity, and assess treatment efficacy.([FOOTNOTE=User Manual (DOC-2044-02 March 2013), pages 3, 123.],[ANCHOR=],[LINK=])
Support early detection of gastrointestinal diseases and functional disorders with a complete portfolio of motility testing products. Medtronic offers esophageal manometry, anorectal manometry, and capsule-based motility testing, enabling you to do full evaluations of GI tract motor function to understand the root cause of GI functional disorders.([FOOTNOTE=Kahrilas PJ. Esophageal motor disorders in terms of high-resolution esophageal pressure topography: what has changed? Am J Gastroenterol. 2010;105:981-7.],[ANCHOR=],[LINK=]),([FOOTNOTE=Conklin J. Color Atlas of High Resolution Manometry. Springer Publishing. 2009. Page 71.],[ANCHOR=],[LINK=]),([FOOTNOTE=Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014;109:1141-57.],[ANCHOR=],[LINK=]),([FOOTNOTE=Carrington EV, Brokjaer A, Craven H, Zarate N, Horrocks EJ, Palit S, et al. Traditional measures of normal anal sphincter function using high-resolution anorectal manometry (HRAM) in 115 healthy volunteers. Neurogastroenterol Motil. 2014;26(5):625-35.],[ANCHOR=],[LINK=])
The Beacon™ EUS delivery system is designed for consistent tissue sample acquisition with intact cell architecture([FOOTNOTE=DDW 2015 Presentations: #935. A Novel EUS-guided Liver Biopsy Needle is Superior to 19-G Core and FNA Needles: Examining the Effect of Needle Design, Number of Excursions, and Variable Suction Parameters on Histologic Yield. Schulman A, Thompson C, Chan W, Ryou M. #Tu1638. Initial experience with a novel EUS-guided core biopsy needle (SharkCore™): a North American multicenter study. DiMaio C, Kolb J , Benias P, et al. #Tu1648. Evaluating The Efficacy of a New FDA Approved EUS Core Biopsy Needle and Different Fine Needle Biopsy (FNB) Techniques To Yield The best Core Specimen In a Live Porcine Model. Shivangi Kothari S, Kothari T, Zhou Z, et al.],[ANCHOR=],[LINK=]),([FOOTNOTE=Based on product development testing data. Data on file. (See Report #1085 and Report #1090).],[ANCHOR=],[LINK=]) and enables fast needle exchange without changing scope position, resulting in reduced procedural time.([FOOTNOTE=Enestvedt B, Maranki, J, Makipour K, Mathur M, Haluszka O. Is two better than one? A comparison of EUS-FNA efficiency of single- vs multi-needle platforms. Gastrointestinal Endoscopy. 2013;77(5S):AB179.],[ANCHOR=],[LINK=]) This innovative system supports early detection that leads to early treatment of GI diseases by improving diagnostic capabilities and helping physicians meet each patient’s individual needs.
Our reflux service line provides actionable information for timely treatment decisions.1-6 These reflux testing products feature both capsule-based and catheter-based technologies, giving physicians the flexibility to offer solutions that best meet their patients' needs.
The Barrx™ radiofrequency ablation system has been proven more effective than surveillance in reducing the risk of disease progression in patients with Barrett’s esophagus.11,12,([FOOTNOTE=Das A, Wells C, Kim HJ, Fleischer DE, Crowell MD, Sharma VK. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett’s esophagus. Endoscopy. 2009;41:400-8.],[ANCHOR=],[LINK=]) In fact, patients with confirmed low-grade dysplasia experienced a 94% reduction in relative risk of progression to high-grade dysplasia or esophageal cancer.12
